Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 1998

View Archived Issues

LeukoSite: year-end 1997 highlights

The effects of NPY antagonist BIBP-3226 on blood pressure and heart rate

Cypress Bioscience: Q4 and year-end 1997 highlights

Gilead: Q4 and year-end 1997 highlights

Genome Therapeutics and Schering-Plough expand antiinfectives alliance

Alliance formed for development of oral vaccines from plants

Lilly expands product options for Ligand

FDA advisory panel to review TMR using Heart Laser System

FDA Advisory Committee will meet to discuss Myotrophin

New potassium channel activators from American Home

Japanese academics collaborate in the study of oral platinum complex

SmithKline Beecham claims indolines for CNS disorders

Allergan develops retinoid-like compounds

Antimigraine agent for nasal or oral administration disclosed by Pierre Fabre

Inhibitors of cholesterol biosynthesis under study at Pfizer

New melanoma immunotherapy approaches show clinical potential

First launch for Synthelabo antihistamine

Patient enrollment complete for Gd-Tex phase II trial

FDA approves ocular antiinflammatory agent

Biomatrix and Novartis sign distribution agreement for Synvisc

Novel anti-HIV compound acts by inhibiting HIV-1 transcription

Taylor acquires anesthetic products from Janssen

Polydex receives continuing funding for contraceptive research

Inex finalizes acquisition of Lynx antisense assets

Detrusitol launched in U.K. and Germany

Antitumor TEPA analogue described by Lithuanian researchers

Bone Care International submits NDA for oral one-alpha D2

Crixivan gets traditional FDA approval

Diovan HCT approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...